Skip to content

The Impact of Etomidate and Propofol Total Intravenous Anesthesia on Postoperative Recovery Quality in Patients Undergoing Ambulatory Laparoscopic Cholecystectomy

The Impact of Etomidate and Propofol Total Intravenous Anesthesia on Postoperative Recovery Quality in Patients Undergoing Ambulatory Laparoscopic Cholecystectomy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095708
Enrollment
Unknown
Registered
2025-01-10
Start date
2025-01-10
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystectomy

Interventions

Etomidate group:During anesthesia induction, a loading dose of etomidate at 0.2–0.4 mg/kg is administered, followed by continuous intravenous infusion of etomidate to maintain the BIS range between 40
Propofol group:During anesthesia induction, a loading dose of propofol at 1.5–2.5 mg/kg is administered, followed by continuous intravenous infusion of propofol to maintain the BIS range between 40 an

Sponsors

The Affiliated Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. Scheduled for ambulatory surgery (patients who plan to stay overnight for social reasons or are unexpectedly hospitalized overnight will still be included in the study); 3. Scheduled to undergo laparoscopic cholecystectomy under general anesthesia; 4. Agrees to participate in this study and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Refusal to participate in this study; 2) ASA grade III or higher; 3) BMI 29.9 kg/m²; 4) History of chronic use of analgesics or sedatives, including benzodiazepines, alcohol abuse, or allergies to etomidate or propofol; 5) History of insomnia; 6) Severe preoperative cognitive impairment with an MMSE score =180 mmHg; 10) Underwent surgery within the past 3 months; participation in another study within the past 30 days; 11) Patients who have taken steroids or other immunosuppressive drugs for more than 10 days within the past 6 months, or have a history of adrenal cortical suppression or immune system disorders.

Design outcomes

Primary

MeasureTime frame
QoR-15 score on postoperative day 1;

Secondary

MeasureTime frame
Postoperative hospital complications (composite complications);Response time to verbal command and extubation time;PACU length of stay;Patient self-reported pain, comfort, and satisfaction with anesthesia;Injection pain;Myoclonus;Time to loss of consciousness;Incidence of hypertension and hypotension;Incidence of delirium within 24 hours postoperatively;Incidence of PONV within 24 hours postoperatively;Severity of nausea within 24 hours postoperatively;Number of vomiting episodes within 24 hours postoperatively;Pain score within 24 hours postoperatively;Sleep quality score on postoperative day 1;Intraoperative awareness;Incidence of complications within 30 days postoperatively;Readmission rate within 30 days postoperatively;Long-term quality of life at 6 and 12 months postoperatively;

Countries

China

Contacts

Public ContactYao Lu

Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University

luyao@ahmu.edu.cn+86 157 5541 2776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026